You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial Completed
582 Analysis of the HR+/HER2- breast cancer tumor microenvironment following immune priming with pelareorep and atezolizumab using imaging mass cytometry – Results from the AWARE-1 trial

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023186011
Dec 20239106
Jan 20243003
Feb 20243801
Mar 20243801
Apr 20243602
May 20243401
Jun 20246306
Jul 20243202
Aug 20242405
Sep 20244406
Oct 20245207
Nov 20243802
Dec 20245002
Jan 20254003
Feb 2025406
Mar 2025008
Apr 2025001
May 2025002
Jun 2025203
Total802078